Chicago, IL – April 30, 2025
Mondego Bio presented new data on its investigational PTPN2 inhibitor ZE00-0388 at the American Association for Cancer Research (AACR) 2025 Annual Meeting, held at the McCormick Place Convention Center in Chicago.
In preclinical studies, ZE00-0388 and related compounds demonstrated clear target engagement, including modulation of the JAK-STAT pathway and enhanced IFNγ secretion in human PBMCs. The molecules also showed strong oral bioavailability and robust activity in tumor models when administered in combination with anti–mPD-1 therapy.
In the subcutaneous MC38 colon cancer model in female C57BL/6 mice, the treatment not only arrested tumor growth but also triggered complete regressions that persisted after discontinuation of anti–mPD-1. Safety and tolerability were favorable across all evaluated doses.
“Our AACR presentation underscores the growing body of evidence supporting ZE00-0388 as a differentiated candidate in immuno-oncology,” said Sanja Baumann-Tomovska, PhD, Head of BD&L at Mondego Bio.